Personalis Inc (PSNL) Actualités

New Nature Medicine Publication Shows ctDNA Levels Linked to Recurrence Risk in Lung Cancer

Results demonstrate the importance of ultra-sensitive ctDNA detection in lung cancer Personalis, Inc. (Nasdaq: PSNL), in collaboration with...

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Form 8-K - Current report

Personalis Reports Preliminary Fourth Quarter and Full Year 2024 Revenue

Full year revenue of ~$84.6 million represents a 15% year-over-year increase Cash balance of ~$185.0 million expected to provide runway to cash...

Form 8-K - Current report

Form 424B5 - Prospectus [Rule 424(b)(5)]

Form 8-K - Current report

Personalis Advances Business Strategy with Investment from Merck and Extends Collaboration with Moderna

Personalis, Inc. (NASDAQ: PSNL) announced today agreements with long time collaborators Merck and Moderna that accelerate the advancement of the...

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Personalis and Tempus Expand Collaboration to Biopharma

Expanded collaboration to yield greater biopharma access to Personalis’ MRD solution Personalis, Inc. (Nasdaq: PSNL) and Tempus AI, Inc. (Nasdaq:...

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Personalis to Participate at Upcoming Investor Conferences

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that its management team will participate...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]